(Q24339404)

identical protein binding

GOA release 2020-03-11

1 reference

GOA release 2020-03-11

author

Christian Siebold

14

1 reference

ORCID Public Data File 2021

Min Lu

1

Min Lu

0 references

Colin R. Goding

Colin R Goding

20

0 references

Stefan Knapp

Stefan Knapp

11

0 references

Benedikt M. Kessler

Benedikt M Kessler

12

0 references

Yvonne Jones

15

E Yvonne Jones

0 references

author name string

Hilde Breyssens

2

0 references

Victoria Salter

3

0 references

Shan Zhong

4

0 references

Ying Hu

5

0 references

Caroline Baer

6

0 references

Indrika Ratnayaka

7

0 references

Alex Sullivan

8

0 references

Nicholas R Brown

9

0 references

Jane Endicott

10

0 references

Mark R Middleton

13

0 references

Elena V Sviderskaya

16

0 references

Jonathan Cebon

17

0 references

Thomas John

18

0 references

Otavia L Caballero

19

0 references

Xin Lu

Amplification of CDK4 and MDM2 in malignant melanoma.

21

0 references

language of work or name

English

0 references

publication date

13 May 2013

0 references

published in

Cancer Cell

0 references

volume

23

0 references

issue

5

0 references

page(s)

618-33

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

ASPP proteins specifically stimulate the apoptotic function of p53

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

MDM4 is a key therapeutic target in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Recurrent patterns of dual RB and p53 pathway inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

A new role for nuclear transport factor 2 and Ran: nuclear import of CapG

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Resistance to MEK inhibitors: should we co-target upstream?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Substrates of mitotic kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

iASPP inhibition: increased options in targeting the p53 family for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021

High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2013.03.013

7 January 2021